In the first 5 months of 2013, 857 deaths were reported in countries under enhanced surveillance.
Novartis nabbed EU approval of Bexsero, a meningitis B vaccine the company has been banking on to bolster its lagging vaccine unit.
Novartis has won European approval of Bexsero, its new meningitis B vaccine, which is central to the Big Pharma's drive to grow its big vaccine unit.
Novartis ($NVS) nabbed European approval for its new meningitis B vaccine Bexsero, for use in patients 2 months of age and older.
Novartis, still riding high on a European Medicine Agency committee backing of its meningitis vaccine Bexsero, confirmed more upbeat results from a study showing the shot offered broad protection to infants.
Health Canada gave the nod to Sanofi Pasteur Canada to expand the indication for Menactra to infants 9 months of age.
Novartis ($NVS) hit a key turning point with its vaccines division when a European Union committee backed the company's Bexsero meningitis shot.
Novartis has scored a key endorsement for one of the brightest stars from its vaccines division. The European Union's Committee for Medicinal Products for Human Use (CHMP) backed approval of Bexsero, the Swiss drug giant's ($NVS) meningitis B vaccine that could become the first such shot to hit the market if the European Commission follows the CHMP's advice.
Novartis' struggling vaccine unit got a shot in the arm today when the European Medicines Agency (EMA) recommended for approval, Bexsero, its potential blockbuster vaccine for meningitis B.
The World Health Organization deemed an inexpensive meningitis vaccine safe out of cold storage for four days, meaning health workers can more easily transport the drug to remote parts of Africa where meningitis A is common.